ÂÜÀòÂÒÂ×

Currently, Dr. Pandey is leading the effort to develop novel medicines for diseases that include retinal diseases and cancer. His areas of expertise, in which he has published 40 scientific papers are: ophthalmology, cancer, angiogenesis and lymphangiogenesis, immuno-oncology, autoimmunity, yeast and drosophila genetics, tight junction biology, and discovery and development of small molecule and peptide therapeutic agents.. Dr. Pandey was an invited speaker at the Homogeneous Time Resolved Fluorescence conference sponsored by Cisbio, the leader in this technology, in Avignon in 2004. In addition to receiving multiple grants from the National Cancer Institute and the National Eye Institute, he has served on multiple NIH grant review panels. Prior to joining AsclepiX Therapeutics, Dr. Pandey joined the Systems Biology lab of Dr. Aleksander Popel at the Johns Hopkins University School of Medicine where he led the study of multiple classes of peptides as therapeutics for retinal diseases and cancer and mentored postdoctoral fellows and PhD students. Dr. Pandey previously held the position of Director of Biology at Alba Therapeutics, a position he held for 3 years. He led the discovery and research for the lead clinical candidate larazotide acetate for celiac disease while there and was responsible for characterizing its mechanism of action. At Alba Therapeutics, Dr. Pandey also led the team that uncovered the mechanism of action of peptides that opened epithelial tight junctions to be used as novel drug delivery agents. Prior to joining Alba Therapeutics, Dr. Pandey spent 7 years as a senior scientist in the Cancer Therapeutics Team at Johnson & Johnson developing drugs for metastatic breast cancer. Dr. Pandey graduated magna cum laude with highest honors in biochemistry from Brandeis University. Dr. Pandey received his Ph.D. in molecular biophysics from Florida State University and completed postdoctoral fellowships at Harvard and MIT in genetics and immunology.